According to the ASAS-EULAR treatment guideline, either an elevated CRP or positive MRI may be taken into consideration for bDMARD therapy in patients with axSpA, irrespective of the presence or absence of radiographic sacroiliitis [15]. The gene discussed is CRP; the disease is Sacroiliac arthritis.